At Limula, we want is to make ex vivo gene-engineered cell therapies accessible to the patients in need. To fulfil this vision, we offer a unique platform technology that can perform every steps of cell therapy manufacturing in a single device, directly at the hospital. With our solution, we increase overall safety and reproducibility of the process by automating unnecessary manual steps; we remove the need for large sterile facilities that are expensive to build and maintain, and for long-distance cryogenic transport of fragile human samples; we lower the number of human operators and, as a consequence, decrease costs to an estimated $50k per patient. Our technology has the potential to catalyse the transition towards the widespread adoption of highly personalised treatments, and radically broaden their accessibility.
Location: Switzerland
Employees: 1-10
Total raised: $6.8M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 10.06.2024 | Verve Vent... | verve.vc |
| 18.05.2022 | Venture Ki... | venturekic... |
| 25.03.2024 | VentureLab | venturelab... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.05.2024 | - | $6.8M | - |
Mentions in press and media 32
| Date | Title | Description |
| 19.03.2026 | Swiss Economic Award 2026: Nine start-ups progress to the final | The Swiss Economic Award recognises outstanding entrepreneurial achievements in the categories of services, deep tech/life sciences and production/industry. Over 150 applications were received for the 2026 edition. From these, nine promisi... |
| 09.02.2026 | Limula transitions to commercial phase | Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single ... |
| 17.09.2025 | 66 alumni from Venture Kick among the Top100 Swiss Startups in 2025 | Venture Kick alumni were highlighted in the fourteenth edition of the Top100 Swiss Startup Awards annual ranking, taking the podium and all of the Top 10 spots. 10 Venture Kick startups ranked in the Top 10: #1 Corintis Corintis is a provid... |
| 04.08.2025 | Three life sciences startups recognized for growth potential | The Innosuisse Innovation Council was impressed by three life sciences startups that completed the Core Coaching program. In recognition of their remarkable progress, the Council awarded them the Innosuisse certificate, signaling their rea... |
| 07.03.2025 | Breakthrough Solution in end-to-end cell therapy manufacturing unveiled | LimONE was officially presented by Luc Henry, CEO of Limula at Advanced Therapies Week in Dallas, Texas, on January 22nd, during the Innovation Zone Tech Spotlight Session. The device unveiled is designed for both hospitals and biopharma c... |
| 11.12.2024 | Limula, Actival and AirCurve get FIT backing | Limula: automating the production of cell therapies to make them more accessible to patients In the treatment of cancers and other currently incurable diseases, cell and gene therapies undoubtedly represent the most disruptive medical innov... |
| 12.07.2024 | Industry experts avail resources to young companies | From the Top 10 selected startups for the Swiss Prime Site Accelerator Program, VAULTED AG, viboo and Resilientsy emerged as finalists, winning a ticked for an intensive Acceleration Programme. They would collaborate with Swiss Prime Site ... |
| 03.06.2024 | Two weeks in Silicon Valley | Until 7 June 2024 eight Swiss startups, selected for the Swissnex bootcamp, will have their temporary base at Pier 17, the headquarters of Swissnex in San Francisco. This bootcamp, part of the Innosuisse Internationalisation Camps, provide... |
| 23.05.2024 | Revolutionizing Cell and Gene Therapy Manufacturing: Limula's $6.8M Seed Round | Limula, a pioneering biotech company established in 2020, has recently secured a substantial $6.8M seed round to transform the landscape of cell and gene therapy manufacturing. This significant funding injection is poised to propel Limula t... |
| 21.05.2024 | Biotech Limula secures $6.8M for gene therapy | Limula has raised a $6.8M seed round to lower costs of life-saving cell and gene therapy products. The company is currently onboarding selected cell therapy developers to run pilots. The money raised will be used to advance software develop... |
Show more